MX9207349A - Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides. - Google Patents
Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides.Info
- Publication number
- MX9207349A MX9207349A MX9207349A MX9207349A MX9207349A MX 9207349 A MX9207349 A MX 9207349A MX 9207349 A MX9207349 A MX 9207349A MX 9207349 A MX9207349 A MX 9207349A MX 9207349 A MX9207349 A MX 9207349A
- Authority
- MX
- Mexico
- Prior art keywords
- osteoporosis
- parathyroid hormone
- bisphosphonates
- methods
- treatment
- Prior art date
Links
- 229940122361 Bisphosphonate Drugs 0.000 title abstract 2
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 2
- 150000004663 bisphosphonates Chemical class 0.000 title abstract 2
- 239000000199 parathyroid hormone Substances 0.000 title abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención provee métodos para mejorar la masa ósea en un ser humano u otro animal que padece de osteoporosis, que comprende un período de tratamiento de 30 días, compuesto de un régimen de administración de hormona de paratiroides y un régimen de administración de bisfosfonato.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80962091A | 1991-12-17 | 1991-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9207349A true MX9207349A (es) | 1993-12-01 |
Family
ID=25201804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9207349A MX9207349A (es) | 1991-12-17 | 1992-12-17 | Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides. |
Country Status (18)
Country | Link |
---|---|
US (1) | US5616560A (es) |
EP (1) | EP0618805A1 (es) |
JP (1) | JPH07502507A (es) |
AU (2) | AU3322593A (es) |
BR (1) | BR9206941A (es) |
CA (1) | CA2124792C (es) |
CZ (1) | CZ282889B6 (es) |
FI (1) | FI942884A (es) |
HU (1) | HUT68010A (es) |
IL (1) | IL104108A (es) |
MA (1) | MA23079A1 (es) |
MX (1) | MX9207349A (es) |
NO (1) | NO942241D0 (es) |
NZ (1) | NZ246456A (es) |
RU (2) | RU2112515C1 (es) |
SK (1) | SK74594A3 (es) |
WO (1) | WO1993011786A1 (es) |
ZA (1) | ZA929758B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993011786A1 (en) * | 1991-12-17 | 1993-06-24 | Procter & Gamble Pharmaceuticals, Inc. | Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone |
JPH08502287A (ja) * | 1992-10-09 | 1996-03-12 | ジ・アップジョン・カンパニー | 抗炎症剤としてのピリミジンビスホスホン酸エステルおよび(アルコキシメチルホスフィニル)アルキルホスホン酸 |
US5496801A (en) * | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
CN1157565A (zh) * | 1994-09-09 | 1997-08-20 | 普罗克特和甘保尔公司 | 用骨活性膦酸盐和甲状旁腺激素治疗骨质疏松症的方法 |
JPH10505091A (ja) * | 1994-09-09 | 1998-05-19 | ザ、プロクター、エンド、ギャンブル、カンパニー | 骨粗鬆症用のホスホネート及び副甲状腺ホルモン |
US5747456A (en) * | 1994-12-19 | 1998-05-05 | Beth Israel Deaconess Medical Center | Continuous low-dose administration of parathyroid hormone or its agonist |
JPH10511095A (ja) * | 1994-12-19 | 1998-10-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | 副甲状腺ホルモン又はその作動薬の低用量継続投与 |
ES2262145T3 (es) * | 1994-12-28 | 2006-11-16 | Gador S.A. | Composicion anabolica para la masa osea que comprende olpadronato. |
US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
EP0891779A1 (de) * | 1997-06-19 | 1999-01-20 | Roche Diagnostics GmbH | Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen |
US6432932B1 (en) | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US6015801A (en) * | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US5994329A (en) * | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US6770623B1 (en) * | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
EP0922467A3 (en) * | 1997-12-12 | 2000-05-24 | Takeda Chemical Industries, Ltd. | Iontophoretic drug delivery |
EP1123401A1 (en) * | 1998-10-22 | 2001-08-16 | The General Hospital Corporation | BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP) |
WO2000032771A1 (en) * | 1998-11-30 | 2000-06-08 | The General Hospital Corporation | Pth1r and pth3r receptors, methods and uses thereof |
SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
AUPQ232599A0 (en) * | 1999-08-19 | 1999-09-09 | Royal Alexandra Hospital For Children, The | Drug for treating fractures |
AU7734800A (en) * | 1999-09-29 | 2001-04-30 | General Hospital Corporation, The | Polypeptide derivatives of parathyroid hormone (pth) |
ATE304856T1 (de) | 2000-06-20 | 2005-10-15 | Novartis Pharma Gmbh | Methode zur verabreichung von biphosphonaten |
CA2372450A1 (en) * | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
KR100491737B1 (ko) * | 2001-07-20 | 2005-05-27 | 주식회사 한국아이템개발 | 공기 정화 기능의 모기 퇴치기 |
CA2454275C (en) | 2001-07-23 | 2012-10-23 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
HUP0401441A3 (en) * | 2001-08-17 | 2012-09-28 | Novartis Ag | 5-cnac as oral delivery agent for parathyroid hormone fragments |
AU2003226148A1 (en) * | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
ES2532393T3 (es) | 2002-05-10 | 2015-03-26 | F. Hoffmann-La Roche Ag | Acidos bisfosfónicos para tratamiento y prevención de osteoporosis |
US20040097468A1 (en) * | 2002-11-20 | 2004-05-20 | Wimalawansa Sunil J. | Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment |
WO2004093902A1 (en) * | 2003-03-19 | 2004-11-04 | The General Hospital Corporation | CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS |
DE602004016995D1 (de) * | 2003-06-26 | 2008-11-20 | Control Delivery Sys Inc | In-situ gelierendes arzneimittelabgabesystem |
EP1653985A4 (en) | 2003-07-17 | 2009-08-05 | Gen Hospital Corp | CONSTRAINTS CONTAINING CONTAINING HORMONE PARATHYROID (PTH) ANALOGUES |
CA2534577A1 (en) * | 2003-08-06 | 2005-02-24 | Rhodia, Inc. | Method for promoting bone growth |
WO2005018640A1 (en) * | 2003-08-20 | 2005-03-03 | The Procter & Gamble Company | Kit for treatment of upper gastrointestinal tract conditions |
US20050261250A1 (en) * | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
CA2628945A1 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
JP2009545320A (ja) * | 2006-08-04 | 2009-12-24 | ザ ジェネラル ホスピタル コーポレイション | 副甲状腺ホルモン(pth)のポリペプチド誘導体 |
KR20120125601A (ko) * | 2007-05-24 | 2012-11-16 | 아블린쓰 엔.브이. | Rank-l에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드 |
KR101661730B1 (ko) | 2007-08-01 | 2016-10-04 | 더 제너럴 하스피탈 코포레이션 | G―단백질 결합 수용체를 이용한 스크리닝 방법 및 관련 조성물 |
JP2013512688A (ja) | 2009-12-07 | 2013-04-18 | ミシガン テクノロジカル ユニバーシティ | クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法 |
US8882740B2 (en) * | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
WO2011143406A2 (en) | 2010-05-13 | 2011-11-17 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
WO2016163886A2 (en) | 2015-04-10 | 2016-10-13 | Clues2Cure International B.V. | Administration of taurine or an analog thereof for the treatment of nerve cell damage |
EP3875105A4 (en) * | 2018-10-29 | 2022-06-29 | Asahi Kasei Pharma Corporation | Method for preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week |
CA3101326C (en) | 2018-10-29 | 2023-08-01 | Asahi Kasei Pharma Corporation | Method for preventing or treating osteoporosis, characterized by administering teriparatide or salt thereof at a frequency of twice a week |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086196A (en) * | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
DE3243358A1 (de) * | 1982-11-24 | 1984-05-24 | Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch | Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose |
US4812304A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Treatment of osteoporosis |
US4812311A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
US4822609A (en) * | 1984-12-21 | 1989-04-18 | The Procter & Gamble Company | Treatment of osteoporosis |
IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
US4761406A (en) * | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
US4833125A (en) * | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
DE3935738A1 (de) * | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
WO1993011786A1 (en) * | 1991-12-17 | 1993-06-24 | Procter & Gamble Pharmaceuticals, Inc. | Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone |
-
1992
- 1992-12-15 WO PCT/US1992/010869 patent/WO1993011786A1/en not_active Application Discontinuation
- 1992-12-15 CZ CZ941477A patent/CZ282889B6/cs not_active IP Right Cessation
- 1992-12-15 NZ NZ246456A patent/NZ246456A/en unknown
- 1992-12-15 RU RU94031209A patent/RU2112515C1/ru active
- 1992-12-15 HU HU9401798A patent/HUT68010A/hu unknown
- 1992-12-15 JP JP5511155A patent/JPH07502507A/ja active Pending
- 1992-12-15 SK SK745-94A patent/SK74594A3/sk unknown
- 1992-12-15 CA CA002124792A patent/CA2124792C/en not_active Expired - Fee Related
- 1992-12-15 AU AU33225/93A patent/AU3322593A/en not_active Withdrawn
- 1992-12-15 BR BR9206941A patent/BR9206941A/pt not_active Application Discontinuation
- 1992-12-15 EP EP93901282A patent/EP0618805A1/en not_active Withdrawn
- 1992-12-16 IL IL10410892A patent/IL104108A/en not_active IP Right Cessation
- 1992-12-16 AU AU30226/92A patent/AU663348B2/en not_active Ceased
- 1992-12-16 MA MA23039A patent/MA23079A1/fr unknown
- 1992-12-16 RU RU92004521A patent/RU2104699C1/ru active
- 1992-12-17 MX MX9207349A patent/MX9207349A/es unknown
- 1992-12-17 ZA ZA929758A patent/ZA929758B/xx unknown
-
1994
- 1994-06-15 NO NO942241A patent/NO942241D0/no unknown
- 1994-06-16 FI FI942884A patent/FI942884A/fi unknown
-
1996
- 1996-03-20 US US08/619,103 patent/US5616560A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0618805A1 (en) | 1994-10-12 |
ZA929758B (en) | 1993-09-10 |
WO1993011786A1 (en) | 1993-06-24 |
SK74594A3 (en) | 1995-01-12 |
US5616560A (en) | 1997-04-01 |
AU3322593A (en) | 1993-07-19 |
NO942241D0 (no) | 1994-06-15 |
CZ282889B6 (cs) | 1997-11-12 |
IL104108A0 (en) | 1993-05-13 |
FI942884A0 (fi) | 1994-06-16 |
MA23079A1 (fr) | 1993-07-01 |
FI942884A (fi) | 1994-06-16 |
RU2104699C1 (ru) | 1998-02-20 |
CA2124792C (en) | 2000-07-04 |
HU9401798D0 (en) | 1994-09-28 |
CA2124792A1 (en) | 1993-06-24 |
BR9206941A (pt) | 1995-05-02 |
RU2112515C1 (ru) | 1998-06-10 |
AU663348B2 (en) | 1995-10-05 |
NO942241L (es) | 1994-08-09 |
NZ246456A (en) | 1997-03-24 |
AU3022692A (en) | 1993-06-24 |
CZ147794A3 (en) | 1994-12-15 |
HUT68010A (en) | 1995-05-29 |
RU94031209A (ru) | 1996-07-27 |
JPH07502507A (ja) | 1995-03-16 |
IL104108A (en) | 1999-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9207349A (es) | Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides. | |
IL78342A (en) | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof | |
BR9711829A (pt) | Implante cirúrgico contendo um marcador radiopaco ressorvìvel. | |
ES2136624T3 (es) | Implante biocompatible para regular la ovulacion en yeguas. | |
GR3030076T3 (en) | Compositions for the treatment of arthritis containing phosphonates and nsaids. | |
RU92004521A (ru) | Применение бисфосфонатов и экстракта паращитовидных желез для лечения остеопороза и набор для лечения | |
YU49170B (sh) | Farmaceutska formulacija na bazi paratiroidnog hormona i raloksifena | |
AU5567790A (en) | Device for reinforcing and sustaining the cap of the rotators of a human shoulder joint | |
HK1004257A1 (en) | Use of droloxifene in the treatment of bone diseases | |
DK0494972T3 (da) | Brusedosisform samt fremgangsmåde til administration heraf | |
ES2190244T3 (es) | Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales. | |
DK0480934T3 (da) | Lægemiddel, der indeholder ephedrin og koffein til behandling af overvægt | |
EP0289314A3 (en) | Use of igf-ii in the treatment of bone disorders | |
NO305581B1 (no) | Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose | |
PL309693A1 (en) | Combined osteoporosis inhibiting treatment | |
RU93054017A (ru) | Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза | |
DK1001802T3 (da) | Farmaceutisk kombinationspræparat af parathyroidhormon og en knogleresorptionsinhibitor | |
KR950702120A (ko) | 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis) | |
IT1222395B (it) | Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare | |
DK0561846T3 (da) | 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning | |
ATE194775T1 (de) | Calcitonin enthaltende pharmazeutische zusammensetzungen | |
MX9704105A (es) | Conjunto para uso en un ciclo terapeutico de tratamiento de la osteoporosis. | |
KR920700224A (ko) | 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제 | |
AR001226A1 (es) | Métodos para el tratamiento de la osteoporosis utilizando fosofonatos activos y hormona paratiroidea |